Edgewise Therapeutics (EWTX) sets GC option price at $43.56
Rhea-AI Filing Summary
Edgewise Therapeutics, Inc. reported that its General Counsel, John R. Moore, received a grant of a stock option covering 65,000 shares of common stock. The option has a corrected exercise price of $43.56 per share, reflecting the fair market value on the grant date, and expires on August 12, 2036. According to the vesting terms, 1/48th of the shares vest each month beginning on September 12, 2026, contingent on his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
MOORE JOHN R
Role
General Counsel
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 65,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 65,000 shares (Direct)
Footnotes (1)
- F1. 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Key Figures
Option Shares Granted: 65,000 shares
Exercise Price: $43.56 per share
Shares Following Transaction: 65,000 options
+3 more
6 metrics
Option Shares Granted
65,000 shares
Stock Option (Right to Buy) granted on 2026-08-12
Exercise Price
$43.56 per share
Corrected exercise price reflecting fair market value on grant date
Shares Following Transaction
65,000 options
Total Stock Options held after reported grant
Vesting Fraction
1/48th per month
Portion of option shares vesting each month beginning 2026-09-12
Vesting Start Date
September 12, 2026
Monthly vesting commences on this date, subject to continued service
Option Expiration Date
August 12, 2036
Expiration of Stock Option (Right to Buy)
Key Terms
Stock Option (Right to Buy), exercise price, fair market value, vesting
4 terms
Stock Option (Right to Buy) financial
"security_title is Stock Option (Right to Buy) with underlying common stock"
exercise price financial
"The correct exercise price is $43.56, which reflects the fair market value"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
fair market value financial
"which reflects the fair market value of the underlying security on the date"
The price a willing buyer and a willing seller would agree on for an asset or security when neither is under pressure and both have access to the same information. Think of it as the market’s neutral estimate of what something is worth, like the price two neighbors would settle on for a car after comparing similar listings. Investors care because fair market value guides buying and selling decisions, tax reporting, portfolio valuation, and how accurately company assets are reflected in financial statements.
vesting financial
"1/48th of the shares subject to the option vest each month"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What insider transaction did Edgewise Therapeutics (EWTX) disclose in this Form 4/A?
Edgewise Therapeutics disclosed a grant of a stock option for 65,000 shares of common stock to its General Counsel, John R. Moore. The option is a compensation-related award with a multi-year monthly vesting schedule and a long-dated expiration in 2036.
What is the corrected exercise price of the EWTX stock options granted to John R. Moore?
The corrected exercise price of the option grant is $43.56 per share. The amendment states the earlier filing showed a zero price due to a clerical error, and this updated price reflects the fair market value on the grant date.
When do John R. Moore’s EWTX stock options start vesting and over what schedule?
The options begin vesting on September 12, 2026, with 1/48th of the shares vesting each month. Vesting continues monthly so long as he remains a service provider, effectively creating a four-year vesting period from that start date.
When do the Edgewise Therapeutics (EWTX) options granted to John R. Moore expire?
The options are scheduled to expire on August 12, 2036. This long expiration period gives a 10-year term from the grant date, during which vested portions of the option can potentially be exercised at the fixed exercise price.
Does the amended EWTX Form 4 indicate any stock sales by John R. Moore?
No, the filing reports only an acquisition of derivative securities via an option grant. It shows no sales of common stock, and the transaction code and summary both indicate a grant or award rather than a disposition.
AI-generated analysis. How Rhea-AI works. Not financial advice.
